Have a personal or library account? Click to login
The Impact of Bacterial Dysbiosis on the Development of Pancreatic Cancer and Its Treatment in Humans? Cover

The Impact of Bacterial Dysbiosis on the Development of Pancreatic Cancer and Its Treatment in Humans?

Open Access
|Jul 2025

References

  1. Adolph T.E., Mayr L., Grabherr F., Schwärzler J., Tilg H.: Pancreas-Microbiota Cross Talk in Health and Disease. Annual review of nutrition, 39, 249–266 (2019) DOI: 10.1146/annurev-nutr-082018-124306
  2. Alonso-Curbelo D. & Lowe S.W.: A gene-environment-induced epigenetic program initiates tumorigenesis. Nature, 590 (7847), 642–648 (2021) DOI: 10.1038/s41586-020-03147-x
  3. Andréasson K., Olofsson T., Lagishetty V., Alrawi Z., Klaassens E., Holster S., Hesselstrand R., Jacobs J.P., Wallman J.K., Volkmann E.R.: Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota. ACR open rheumatology, 6 (7), 421–427 (2024) DOI: 10.1002/acr2.11673
  4. Aykut B. & Miller G. et al.: The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature, 574 (7777), 264–267 (2019) DOI: 10.1038/s41586-019-1608-2
  5. Baylin S.B. & Jones P.A.: Epigenetic Determinants of Cancer. Cold Spring Harbor perspectives in biology, 8 (9), a019505 (2016) DOI: 10.1101/cshperspect.a019505
  6. Chen X., Zeh H.J., Kang R., Kroemer G., Tang D.: Cell death in pancreatic cancer: from pathogenesis to therapy. Nature reviews. Gastroenterology & hepatology, 18 (11), 804–823 (2021) DOI: 10.1038/s41575-021-00486-6
  7. Chen T. & Liu S. et al.: Alterations of commensal microbiota are associated with pancreatic cancer. The International journal of biological markers, 38 (2), 89–98 (2023) DOI: 10.1177/03936155231166721
  8. Daley D. & Miller G. et al.: NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. The Journal of experimental medicine, 214 (6), 1711–1724 (2017) DOI: 10.1084/jem.20161707
  9. Daley D.: The role of the microbiome in pancreatic oncogenesis. International immunology, 34 (9), 447–454 (2022) DOI: 10.1093/intimm/dxac036
  10. Del Castillo E. & Michaud D. S. et al.: The Microbiomes of Pancreatic and Duodenum Tissue Overlap and Are Highly Subject Specific but Differ between Pancreatic Cancer and Noncancer Subjects. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 28 (2), 370–383 (2019) DOI: 10.1158/1055-9965.EPI-18-0542
  11. Dewhirst F.E., Chen T., Izard J., Paster B.J., Tanner A.C., Yu W.H., Lakshmanan A., Wade W.G.: The human oral microbiome. Journal of Bacteriology, 192 (19), 5002-17 (2010) DOI: 10.1128/JB.00542-10
  12. Dickson I.: Microbiome promotes pancreatic cancer. Nature reviews. Gastroenterology & hepatology, 15 (6), 328 (2018) DOI: 10.1038/s41575-018-0013-x
  13. Edogawa S. & Grover M. et al.: Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut, 69 (1), 62–73 (2020) DOI: 10.1136/gut-jnl-2018-317416
  14. Fan X. & Ahn J. et al.: Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut, 67 (1), 120–127 (2018) DOI: 10.1136/gutjnl-2016-312580
  15. Fitzgerald A.A. & Weiner L.M. et al.: DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer, 9 (11), e002837 (2021) DOI: 10.1136/jitc-2021-002837
  16. Fulop D.J., Zylberberg H.M., Wu Y.L., Aronson A., Labiner A.J., Wisnivesky J., Cohen D.J., Sigel K.M., Lucas A.L.: Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. JAMA network open, 6 (3), e234254 (2023) DOI: 10.1001/jamanetworkopen.2023.4254
  17. Geller L.T. & Straussman R. et al.: Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science (New York, N.Y.), 357 (6356), 1156–1160 (2017) DOI: 10.1126/science.aah5043
  18. Gentiluomo M., Canzian F., Nicolini A., Gemignani F., Landi S., Campa D.: Germline genetic variability in pancreatic cancer risk and prognosis. Seminars in cancer biology, 79, 105–131 (2022) DOI: 10.1016/j.semcancer.2020.08.003
  19. Gnanasekaran J. & Nussbaum G. et al.: Intracellular Porphyromonas gingivalis Promotes the Tumorigenic Behavior of Pancreatic Carcinoma Cells. Cancers, 12 (8), 2331 (2020) DOI: 10.3390/cancers12082331
  20. Goggins M. & Bruno M. et al.: Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 69 (1), 7–17 (2020) DOI: 10.1136/gutjnl-2019-319352
  21. Grant T.J., Hua K., Singh A.: Molecular Pathogenesis of Pancreatic Cancer. Progress in molecular biology and translational science, 144, 241–275 (2016) DOI: 10.1016/bs.pmbts.2016.09.008
  22. Guerra C., Schuhmacher A.J., Cañamero M., Grippo P.J., Verdaguer L., Pérez-Gallego L., Dubus P., Sandgren E.P., Barbacid M.: Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer cell, 11 (3), 291–302 (2007) DOI: 10.1016/j.ccr.2007.01.012
  23. Half E. & Gophna U. et al.: Fecal microbiome signatures of pancreatic cancer patients. Scientific reports, 9 (1), 16801 (2019) DOI: 10.1038/s41598-019-53041-4
  24. Hirabayashi M. & Tsugane S. et al.: Helicobacter pylori infection, atrophic gastritis, and risk of pancreatic cancer: A population-based cohort study in a large Japanese population: the JPHC Study. Scientific reports, 9 (1), 6099 (2019) DOI: 10.1038/s41598-019-42365-w
  25. Hsu W.Y., Lin C.H., Lin C.C., Sung F.C., Hsu C.P., Kao C.H.: The relationship between Helicobacter pylori and cancer risk. European journal of internal medicine, 25 (3), 235–240 (2014) DOI: 10.1016/j.ejim.2014.01.009
  26. Huang, J. & Ye W. et al.: Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: A nested case-control study. International journal of cancer, 140 (8), 1727–1735 (2017) DOI: 10.1002/ijc.30590
  27. Human Oral Microbiome Database V3.1 https://www.homd.org/
  28. Iglesia D., Avci B., Kiriukova M., Panic N., Bozhychko M., Sandru V., de-Madaria E., Capurso G.: Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis. United European gastroenterology journal, 8 (9), 1115–1125 (2020) DOI: 10.1177/2050640620938987
  29. Imai H. & Ishioka C. et al.: Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study. Cancer management and research, 11, 7953–7965 (2019) DOI: 10.2147/CMAR.S215697
  30. Kaci G. & Delorme C. et al.: Anti-inflammatory properties of Streptococcus salivarius, a commensal bacterium of the oral cavity and digestive tract. Applied and environmental microbiology, 80 (3), 928–934 (2014) DOI: 10.1128/AEM.03133-13
  31. Kostic A.D. & Garrett W.S. et al.: Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell host & microbe, 14 (2), 207–215 (2013) DOI: 10.1016/j.chom.2013.07.007
  32. Le D.T. & Laheru D.A. et al.: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Journal of immunotherapy (Hagerstown, Md.: 1997), 36 (7), 382–389 (2013) DOI: 10.1097/CJI.0b013e31829fb7a2
  33. Lu H. & Li L. et al.: Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. Journal of oral microbiology, 11 (1), 1563409 (2019) DOI: 10.1080/20002297.2018.1563409
  34. Maekawa T. & Miyoshi E. et al.: Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochemical and biophysical research communications, 506 (4), 962–969 (2018) DOI: 10.1016/j.bbrc.2018.10.169
  35. Maev I. V., Levchenko A. I., Galeeva J. S., Andreev D. N., Osipenko J. V., Bordin D. S., Ilyina E. N.: Comparative analysis of the intestinal microbiota in patients with exocrine pancreatic insufficiency of various severity. Terapevticheskii Arkhiv, 95 (2), 130-139 (2023) DOI: 10.26442/00403660.2023.02.202056
  36. Maisonneuve P., Lowenfels A. B.: Risk factors for pancreatic cancer: a summary review of meta-analytical studies. International journal of epidemiology, 44 (1), 186–198 (2015) DOI: 10.1093/ije/dyu240
  37. Maitra A., Topol E.J.: Early detection of pancreatic cancer and AI risk partitioning. Lancet (London, England), 403 (10435), 1438 (2024) DOI: 10.1016/S0140-6736(24)00690-1
  38. Meng C., Bai C., Brown T.D., Hood L.E., Tian Q.: Human Gut Microbiota and Gastrointestinal Cancer. Genomics, proteomics & bioinformatics, 16 (1), 33–49 (2018) DOI: 10.1016/j.gpb.2017.06.002
  39. Michaud D.S. & Riboli E. et al.: Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut, 62 (12), 1764–1770 (2013) DOI: 10.1136/gutjnl-2012-303006
  40. Mitsuhashi K. & Shinomura Y. et al.: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget, 6 (9), 7209–7220 (2015) DOI: 10.18632/oncotarget.3109
  41. Montenegro M.L., Corral J.E., Lukens F.J., Ji B., Kröner P.T., Farraye F.A., Bi Y.: Pancreatic Disorders in Patients with Inflammatory Bowel Disease. Digestive diseases and sciences, 67 (2), 423–436 (2022) DOI: 10.1007/s10620-021-06899-2
  42. Nagata N. & Kawai T. et al.: Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study. Gastroenterology, 163 (1), 222–238 (2022) DOI: 10.1053/j.gastro.2022.03.054
  43. Nearing J.T., DeClercq V., Van Limbergen J., Langille M.G.I.: Assessing the Variation within the Oral Microbiome of Healthy Adults. mSphere, 5 (5), e00451-20 (2020) DOI: 10.1128/mSphere.00451-20
  44. Nejman D. & Straussman R. et al.: The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science (New York, N.Y.), 368 (6494), 973–980 (2020) DOI: 10.1126/science.aay9189
  45. Nii T. & Takeda K. et al.: Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis. Annals of the rheumatic diseases, 82 (5), 621–629 (2023) DOI: 10.1136/ard-2022-222881
  46. Nishiyama H., Nagai T., Kudo M., Okazaki Y., Azuma Y., Watanabe T., Goto S., Ogata H., Sakurai T.: Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. Biochemical and biophysical research communications, 495 (1), 273–279 (2018) DOI: 10.1016/j.bbrc.2017.10.130
  47. O’Reilly E.M. & Philip P.A. et al.: Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA oncology, 5 (10), 1431–1438 (2019) DOI: 10.1001/jamaoncol.2019.1588
  48. Parada Venegas D., De la Fuente M.K., Landskron G., González M.J., Quera R., Dijkstra G., Harmsen H.J.M., Faber K.N., Hermoso M.A. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Frontiers in immunology, 10, 277 (2019) DOI: 10.3389/fimmu.2019.00277
  49. PDQ Adult Treatment Editorial Board. Pancreatic Cancer Treatment (PDQ®): Patient Version. In PDQ Cancer Information Summaries. National Cancer Institute (US). (2024)
  50. Pietzner M., Budde K., Rühlemann M., Völzke H., Homuth G., Weiss F.U., Lerch M.M., Frost F.: Exocrine Pancreatic Function Modulates Plasma Metabolites Through Changes in Gut Microbiota Composition. The Journal of clinical endocrinology and metabolism, 106 (5), e2290–e2298 (2021) DOI: 10.1210/clinem/dgaa961
  51. Plottel C.S., Blaser M.J.: Microbiome and malignancy. Cell host & microbe, 10 (4), 324–335 (2011) DOI: 10.1016/j.chom.2011.10.003
  52. Pourali G. & Avan A. et al.: Microbiome as a biomarker and therapeutic target in pancreatic cancer. BMC microbiology, 24 (1), 16 (2024) DOI: 10.1186/s12866-023-03166-4
  53. Pushalkar S. & Miller G. et al.: The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer discovery, 8 (4), 403–416 (2018) DOI: 10.1158/2159-8290.CD-17-1134
  54. Ramanathan R.K. & Von Hoff D.D. et al.: Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Annals of oncology: official journal of the European Society for Medical Oncology, 27 (4), 648–653 (2016) DOI: 10.1093/annonc/mdw020
  55. Ren Z. & Zheng S. et al.: Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 8 (56), 95176–95191 (2017) DOI: 10.18632/oncotarget.18820
  56. Riquelme E. & McAllister F. et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 178 (4), 795–806.e12 (2019) DOI: 10.1016/j.cell.2019.07.008
  57. Risch H.A., Lu L., Kidd M.S., Wang J., Zhang W., Ni Q., Gao Y.T., Yu H.: Helicobacter pylori seropositivities and risk of pancreatic carcinoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23 (1), 172–178 (2014) DOI: 10.1016/j.cell.2019.07.008
  58. Risch H.A.: Pancreatic cancer: Helicobacter pylori colonization, N-nitrosamine exposures, and ABO blood group. Molecular carcinogenesis, 51 (1), 109–118 (2012) DOI: 10.1002/mc.20826
  59. Sabater L. & de-Madaria E. et al.: Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Annals of surgery, 264 (6), 949–958 (2016) DOI: 10.1097/SLA.0000000000001732
  60. Santucci C., Mignozzi S., Malvezzi M., Boffetta P., Collatuzzo G., Levi F., La Vecchia C., Negri E.: European cancer mortality predictions for the year 2024 with focus on colorectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology, 35 (3), 308–316 (2024) DOI: 10.1016/j.annonc.2023.12.003
  61. Seifert L. & Miller G. et al.: The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature, 532 (7598), 245–249 (2016) DOI: 10.1038/nature17403
  62. Sevcikova A., Izoldova N., Stevurkova V., Kasperova B., Chovanec M., Ciernikova S., Mego M.: The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy. International journal of molecular sciences, 23 (1), 488 (2022) DOI: 10.3390/ijms23010488
  63. Sexton R.E. & Azmi A.S. et al.: Connecting the Human Microbiome and Pancreatic Cancer. Cancer metastasis reviews, 41 (2), 317–331 (2022) DOI: 10.1007/s10555-022-10022-w
  64. Shi H., Tsang Y., Yang Y., Chin H.L.: Identification of ONECUT3 as a stemness-related transcription factor regulating NK cell-mediated immune evasion in pancreatic cancer. Scientific reports, 13 (1), 18133 (2023) https://doi.org/10.3390/ijms26020515
  65. Shin J.H., Seeley R.J.: Reg3 Proteins as Gut Hormones? Endocrinology, 160 (6), 1506–1514 (2019) DOI: 10.1210/en.2019-00073
  66. Siegel R.L., Giaquinto A.N., Jemal A.: Cancer statistics, 2024. CA: a cancer journal for clinicians, 74 (1), 12–49 (2024) DOI: 10.3322/caac.21820
  67. Siegel R.L., Miller K.D., Wagle N.S., Jemal A.: Cancer statistics, 2023. CA: a cancer journal for clinicians, 73 (1), 17–48 (2023) DOI: 10.3322/caac.21763
  68. Speth C., Bellotti R., Schäfer G., Rambach G., Texler B., Thurner G.C., Öfner D., Lass-Flörl C., Maglione M.: Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment. Current oncology (Toronto, Ont.), 29 (12), 9833–9854 (2022) DOI: 10.3390/curroncol29120773
  69. Stanciu S., Ionita-Radu F., Stefani C., Miricescu D., Stanescu-Spinu I.I., Greabu M., Ripszky Totan A., Jinga M.: Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects. International journal of molecular sciences, 23 (17), 10132 (2022) DOI: 10.3390/ijms231710132
  70. Frost F. & Lerch M.M. et al.: Impaired Exocrine Pancreatic Function Associates With Changes in Intestinal Microbiota Composition and Diversity. Gastroenterology, 156(4), 1010– 1015 (2019) DOI: 10.1053/j.gastro.2018.10.047
  71. Farrell J.J., Zhang L., Zhou H., Chia D., Elashoff D., Akin D., Paster B.J., Joshipura K., Wong D.T.: Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut, 61 (4), 582–588 (2012) DOI: 10.1136/gutjnl-2011-300784
  72. Stein-Thoeringer C.K. & Ilmer M. et al.: Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreatic Cancer. Annals of surgery, 281 (4), 615–623. (2025) DOI: 10.1097/SLA.0000000000006210
  73. Thomas R.M., Jobin C.: Microbiota in pancreatic health and disease: the next frontier in microbiome research. Nature reviews. Gastroenterology & hepatology, 17 (1), 53–64 (2020) DOI: 10.1038/s41575-019-0242-7
  74. Ubachs J. & Rensen S.S. et al.: Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients. Journal of cachexia, sarcopenia and muscle, 12 (6), 2007–2021 (2021) DOI: 10.1002/jcsm.12804
  75. Ungureanu B.S. & Surlin P. et al.: Could there be an interplay between periodontal changes and pancreatic malignancies? World journal of clinical cases, 11 (3), 545–555 (2023) DOI: 10.12998/wjcc.v11.i3.545
  76. Vujasinovic M., Valente R., Del Chiaro M., Permert J., Löhr J.M.: Pancreatic Exocrine Insufficiency in Pancreatic Cancer. Nutrients, 9 (3), 183 (2017) DOI: 10.3390/nu9030183
  77. Wang S.S., Xu J., Ji K.Y., Hwang C.I.: Epigenetic Alterations in Pancreatic Cancer Metastasis. Biomolecules, 11 (8), 1082 (2021) DOI: 10.3390/biom11081082
  78. Wang Y., Zhang F.C., Wang Y.J.: Helicobacter pylori and pancreatic cancer risk: a meta-analysis based on 2,049 cases and 2,861 controls. Asian Pacific journal of cancer prevention: APJCP, 15 (11), 4449–4454 (2014) DOI: 10.7314/apjcp.2014.15.11.4449
  79. Wei A.L. & Fu M.R. et al.: Oral microbiome and pancreatic cancer. World journal of gastroenterology, 26 (48), 7679–7692 (2020) DOI: 10.3748/wjg.v26.i48.7679
  80. Wu R.T., Wang L.F., Yao Y.F., Sang T., Wu Q.L., Fu W.W., Wan M., Li W. J.: Activity fingerprinting of polysaccharides on oral, gut, pancreas and lung microbiota in diabetic rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 155, 113681 (2022) DOI: 10.1016/j.biopha.2022.113681
  81. Xu W., Zhou X., Yin M., Gao J., Weng Z., Xu C.: The relationship between Helicobacter pylori and pancreatic cancer: a meta-analysis. Translational cancer research, 11 (8), 2810–2822 (2022) DOI: 10.21037/tcr-21-2803
  82. Yang Q., Zhang J., Zhu Y.: Potential Roles of the Gut Microbiota in Pancreatic Carcinogenesis and Therapeutics. Frontiers in cellular and infection microbiology, 12, 872019 (2022) DOI: 10.3389/fcimb.2022.872019
  83. Yu Q., Newsome R.C., Beveridge M., Hernandez M.C., Gharaibeh R.Z., Jobin C., Thomas R.M.: Intestinal microbiota modulates pancreatic carcinogenesis through intratumoral natural killer cells. Gut microbes, 14 (1), 2112881 (2022) DOI: 10.1080/19490976.2022.2112881
  84. Yu T. & Fang J.Y. et al.: Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell, 170 (3), 548–563.e16. (2017) DOI: 10.1016/j.cell.2017.07.008
  85. Zhang S., Yang Y., Weng W., Guo B., Cai G., Ma Y., Cai S.: Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. Journal of experimental & clinical cancer research: CR, 38 (1), 14. (2019) DOI: 10.1186/s13046-018-0985-y
  86. Zhou C.H. & Zou D.W. et al.: Altered diversity and composition of gut microbiota in Chinese patients with chronic pancreatitis. Pancreatology (IAP), 20 (1), 16–24 (2020) DOI: 10.1016/j.pan.2019.11.013
DOI: https://doi.org/10.2478/am-2025-0007 | Journal eISSN: 2545-3149 | Journal ISSN: 0079-4252
Language: English, Polish
Page range: 74 - 85
Submitted on: Mar 7, 2025
|
Accepted on: Jun 9, 2025
|
Published on: Jul 8, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Agata Mikołajczyk, Amelia Wardak, Stanisław Głuszek, Wioletta Adamus-Białek, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.